## **Core Concept**
The question tests the understanding of drug interactions and contraindications in patients with multiple conditions, specifically glaucoma and bronchial asthma. It requires knowledge of the pharmacological properties of various drugs, particularly their effects on intraocular pressure (IOP) and airway resistance.

## **Why the Correct Answer is Right**
The correct answer, , is a non-selective beta-blocker. Non-selective beta-blockers can worsen bronchial asthma by blocking beta-2 receptors in the lungs, leading to bronchoconstriction. In glaucoma, beta-blockers are actually used to decrease intraocular pressure by reducing aqueous humor production. However, in a patient with asthma, the potential for inducing bronchospasm makes non-selective beta-blockers like a risky choice.

## **Why Each Wrong Option is Incorrect**
* **Option A:** - This option might be incorrect because it could represent a drug that is not typically used for glaucoma or is not a beta-blocker, thus not posing a significant risk for asthma patients in terms of bronchoconstriction.
* **Option B:** - If this option represents a selective beta-1 blocker or another class of drug not contraindicated in asthma, it would be incorrect because it does not pose the same level of risk for bronchospasm as non-selective beta-blockers.
* **Option D:** - This could be a drug that is actually used in the treatment of glaucoma without significant effects on airway resistance or even beneficial in patients with asthma, making it a safer choice.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that in patients with glaucoma and asthma, it's crucial to avoid non-selective beta-blockers due to their potential to precipitate bronchospasm. Instead, consider using medications that are either selective beta-1 blockers or have a different mechanism of action for glaucoma that does not adversely affect the airways.

## **Correct Answer: .**